Ani Pharmaceuticals Inc (ANIP)
- Sector
- Pharmaceuticals
- Last price
- $71.71
- As of
Kresmion compiles this page from ANIP's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ANI PHARMACEUTICALS INC (ANIP): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-24.
See the full ANIP dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ANIP on one page. Preview it with sample data, then open it live with a free account.
Preview the ANIP dossierActive events for ANIP
- mediumEarnings above estimates
Q2-2026: Beat consensus by 5.7%, EPS $2.21 vs $2.0911 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 68% of ANIP (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +133% to ANIP (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +1101% to ANIP (2026Q2)
- high13F: large increase
Point72 Asset Management, L.P. added +219% to ANIP (2026Q2)
FREE, NO ACCOUNT
Every event on ANIP, as it fires
You are seeing 5 of 7 events recorded on ANIP since 2026-07-29.
The five above landed across 2 days. The other 2 were recorded on 1 other days. 5 of the 7 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ANIP (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 00182CAC7 · 2026Q2 | $62M | 0.07% | , |
| CITADEL ADVISORS LLCCUSIP 00182CAC7 · 2026Q2 | $45.4M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 00182C103 · 2026Q2 | $42M | 0.02% | , |
| D. E. Shaw & Co., Inc.CUSIP 00182C103 · 2026Q2 | $14.5M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 00182C103 · 2026Q2 | $8M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 00182C103 · 2026Q2 | $5.3M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 00182C103 · 2026Q2 | $5.3M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ANIP
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ANIP against its peers
ANIP's operating margin of 12.6% ranks in the 57th percentile of 19 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | ANIP | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 883M USD | 451M USD | 80 | 21 |
| Gross margin | n/a | 73.3% | n/a | 11 |
| Operating margin | 12.6% | 2.6% | 57 | 19 |
| Net margin | 8.9% | -2.6% | 83 | 20 |
| Return on equity | 14.5% | -19.3% | 75 | 21 |
| P / E | 21.6x | 15.6x | 75 | 9 |
Peers (25): NUVB, OCUL, PAHC, GPCR, INVA, PCRX, TRVI, XERS, NKTR, OMER, HRMY, SUPN, AMPH, BHC, ANRO, ALMS, ESPR.D, TARS, AMLX, OGN, COLL, LQDA, ACRS, AMRX, AXSM. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ANIP: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ANIP on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ANIP for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.